Estimated HF rates by radiotherapy dose and anthracycline treatment
| . | Treated without anthracyclines . | Treated with anthracyclines . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | No. of cases . | No. of controls . | RR . | 95% CI . | No. of cases . | No. of controls . | RR . | 95% CI . |
| MHD (EQD2) | ||||||||
| 0-25 Gy | 28 | 153 | 1.00 | 0.67-1.48 | 20 | 48 | 2.92 | 1.35-6.30 |
| 26-30 Gy | 22 | 49 | 2.43 | 1.51-3.91 | 5 | 8 | 7.09 | 2.56-19.67 |
| ≥31 Gy | 10 | 17 | 3.67 | 1.86-7.25 | 6 | 3 | 10.71 | 3.51-32.67 |
| MLVD (EQD2) | ||||||||
| 0-15 Gy | 26 | 133 | 1.00 | 0.68-1.47 | 17 | 40 | 2.60 | 1.21-5.58 |
| 16-20 Gy | 17 | 60 | 1.43 | 0.85-2.44 | 3 | 8 | 3.74 | 1.31-10.73 |
| ≥21 Gy | 17 | 26 | 3.10 | 1.87-5.14 | 11 | 11 | 8.06 | 3.05-21.32 |
| V30 left ventricle, % | ||||||||
| 0-24 | 9 | 51 | 1.00 | 4 | 16 | 3.36 | 1.57-7.22 | |
| 25-100 | 51 | 168 | 2.57 | 1.25-5.29 | 27 | 43 | 8.65 | 2.83-26.41 |
| V20 left ventricle, % | ||||||||
| 0-49 | 26 | 118 | 1.00 | 14 | 34 | 2.84 | 1.36-5.97 | |
| 50-100 | 34 | 101 | 1.58 | 0.94-2.67 | 17 | 25 | 4.50 | 1.85-10.98 |
| . | Treated without anthracyclines . | Treated with anthracyclines . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | No. of cases . | No. of controls . | RR . | 95% CI . | No. of cases . | No. of controls . | RR . | 95% CI . |
| MHD (EQD2) | ||||||||
| 0-25 Gy | 28 | 153 | 1.00 | 0.67-1.48 | 20 | 48 | 2.92 | 1.35-6.30 |
| 26-30 Gy | 22 | 49 | 2.43 | 1.51-3.91 | 5 | 8 | 7.09 | 2.56-19.67 |
| ≥31 Gy | 10 | 17 | 3.67 | 1.86-7.25 | 6 | 3 | 10.71 | 3.51-32.67 |
| MLVD (EQD2) | ||||||||
| 0-15 Gy | 26 | 133 | 1.00 | 0.68-1.47 | 17 | 40 | 2.60 | 1.21-5.58 |
| 16-20 Gy | 17 | 60 | 1.43 | 0.85-2.44 | 3 | 8 | 3.74 | 1.31-10.73 |
| ≥21 Gy | 17 | 26 | 3.10 | 1.87-5.14 | 11 | 11 | 8.06 | 3.05-21.32 |
| V30 left ventricle, % | ||||||||
| 0-24 | 9 | 51 | 1.00 | 4 | 16 | 3.36 | 1.57-7.22 | |
| 25-100 | 51 | 168 | 2.57 | 1.25-5.29 | 27 | 43 | 8.65 | 2.83-26.41 |
| V20 left ventricle, % | ||||||||
| 0-49 | 26 | 118 | 1.00 | 14 | 34 | 2.84 | 1.36-5.97 | |
| 50-100 | 34 | 101 | 1.58 | 0.94-2.67 | 17 | 25 | 4.50 | 1.85-10.98 |
There was no significant interaction on a multiplicative scale between anthracycline treatment and either MHD or MLVD (see supplemental Table 5A-B). Therefore, estimates of HF rates by radiotherapy dose and anthracycline treatment were calculated under the assumption that there was no multiplicative interaction between the 2. Estimates allowing for an interaction between radiotherapy dose and anthracycline treatment are given in supplemental Table 6.